Two randomized controlled trials concerning 60 elderly patients with chronic heart failure have illustrated that YQFM combined with basic treatment effectively reduced serum NT-proBNP levels and increased EF and 6-min walking distance (6 MWD) compared to basic treatment alone, suggesting the positive effects of YQFM on cardiac function and exercise tolerance (Zhang et al., 2015; Yang et al., 2016). The gene discussed is NPPB; the disease is congestive heart failure.